Clinical Trial

A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Name: A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) — clinical trial record (NCT07508995)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is an open-label, single-arm, phase II study which will assess the safety and efficacy of BGB16673 in combination with sonrotoclax as a time-limited approach for participants with treatment-naive CLL/SLL.

Trial Details

NCT Number	NCT07508995
Lead Sponsor	M.D. Anderson Cancer Center
Conditions	Chronic Lymphocytic Leukemia (CLL)
Enrollment	40 participants
Start Date	2026-09-01
Primary Completion	2031-07-01 (estimated)
Study Completion	2033-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-03